Northwire Canada EditionThursday, July 16, 2026
Northwire
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
M&A / Property

Hydreight to distribute HSC's at-home STI testing kits

NURS · Price

Executive Summary

  • Hydreight Technologies Inc. has entered the at-home sexually transmitted infection (STI) prescreening market through an exclusive distribution agreement with Health Screen Collective (HSC).
  • The company has secured approximately 50,000 pre-orders for HSC's at-home STI prescreen testing kits, with deliveries scheduled to begin in early 2026.
  • The agreement positions Hydreight to leverage its existing mobile clinic and digital health infrastructure to integrate prescreening results with licensed medical review, confirmatory testing, and treatment coordination.

Key Details

  • Agreement Structure: Exclusive distribution agreement granting Hydreight rights to distribute HSC's at-home STI prescreen testing kits across its national platform.
  • Commercial Traction: Approximately 50,000 pre-orders secured from enterprise partners, health care operators, and distribution channels.
  • Timeline: Deliveries of testing kits are expected to begin in early 2026.
  • Product Technology: HSC kits utilize validated lateral-flow immunoassay technology to deliver results in minutes rather than days.
  • Tested Pathogens: The kits provide prescreening for:
    • Chlamydia trachomatis
    • Neisseria gonorrhoeae
    • Trichomonas vaginalis
    • Mycoplasma genitalium
    • Candida albicans
    • Gardnerella vaginalis
  • Performance Metrics: Product validation data indicates high levels of sensitivity, specificity, and overall accuracy, with performance characteristics comparable to commonly used laboratory-based screening methods for initial detection.
  • Strategic Integration: The prescreening tool is integrated into Hydreight’s platform to facilitate a seamless workflow from prescreening to licensed medical review, confirmatory testing, clinical consultation, and treatment coordination.
  • Platform Leverage: Hydreight views this offering as a driver for repeat engagement, downstream clinical services, pharmacy fulfillment, and long-term platform utilization, rather than a standalone product.

Notable Quotes

  • "This category highlights exactly why our platform exists," said Shane Madden, chief executive officer of Hydreight. "When you combine fast, at-home screening with licensed providers and national fulfilment, you remove friction from a category that desperately needs it. That's where real health care transformation happens."
Read the original news release →

More from Hydreight Technologies Inc